MERRIMACK PHARMACEUTICALS IN (MACK) Stock Price & Overview
NASDAQ:MACK • US5903282094
The current stock price of MACK is 15.13 USD. Today MACK is down by 0%. In the past month the price increased by 2.79%. In the past year, price increased by 18.95%.
MACK Key Statistics
- Market Cap
- 223.773M
- P/E
- 1.09
- Fwd P/E
- N/A
- EPS (TTM)
- 13.86
- Dividend Yield
- 99.80%
MACK Stock Performance
MACK Stock Chart
MACK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MACK. When comparing the yearly performance of all stocks, MACK turns out to be only a medium performer in the overall market: it outperformed 66.97% of all stocks.
MACK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MACK. No worries on liquidiy or solvency for MACK as it has an excellent financial health rating, but there are worries on the profitability.
MACK Earnings
MACK Forecast & Estimates
MACK Groups
Sector & Classification
MACK Financial Highlights
Over the last trailing twelve months MACK reported a non-GAAP Earnings per Share(EPS) of 13.86. The EPS increased by 10764.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 82.05% | ||
| ROE | 90.44% | ||
| Debt/Equity | 0 |
MACK Ownership
MACK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.27 | 402.577B | ||
| AMGN | AMGEN INC | 16.17 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.56 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.71 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 16 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.6 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.52 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.98 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MACK
Company Profile
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Company Info
IPO: 2012-03-29
MERRIMACK PHARMACEUTICALS IN
One Broadway, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Gary L. Crocker
Employees: 0
Phone: 16174411000
MERRIMACK PHARMACEUTICALS IN / MACK FAQ
What does MACK do?
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
What is the stock price of MERRIMACK PHARMACEUTICALS IN today?
The current stock price of MACK is 15.13 USD.
Does MACK stock pay dividends?
MERRIMACK PHARMACEUTICALS IN (MACK) has a dividend yield of 99.8%. The yearly dividend amount is currently 0.
What is the ChartMill technical and fundamental rating of MACK stock?
MACK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of MACK stock?
MERRIMACK PHARMACEUTICALS IN (MACK) operates in the Health Care sector and the Biotechnology industry.